Search

Your search keyword '"Latif, Zill‐e‐Huma"' showing total 19 results
Start Over Author "Latif, Zill‐e‐Huma"
19 results on '"Latif, Zill‐e‐Huma"'

5. Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial

Author

Opheim, Arild, Gaulen, Zhanna, Solli, Kristin Klemmetsby, Latif, Zill-E-Huma, Fadnes, Lars T., Saltyte Benth, Jurate, Kunøe, Nikolaj, and Tanum, Lars Håkon Reiestad

Abstract

Background and Objectives Compare the risk of relapse to heroin and other illicit opioids among opioid-dependent patients receiving treatment with extended-release naltrexone (XR-NTX) or buprenorphine-naloxone (BP-NLX). Methods Re-analyzed data from a 12-week multicenter, open-label, randomized treatment study with a subsequent 36-week open-label follow-up study. All patients, N = 143, had completed detoxification and received at least one dose of study medication. Results Of 143 patients (72% men), mean age 36 years, 71 received XR-NTX and 72 BP-NLX. The risk of first relapse and the risk of any relapse to heroin and other illicit opioids were both significantly lower in the XR-NTX group compared with the BP-NLX group (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.28-0.76; P = .002, and HR, 0.11; 95% CI, 0.04-0.29; P

Published
2021

8. Long-Term Effectiveness, Psychiatric Distress, and Chronic Pain in Opioid-Dependent Individuals Receiving Treatment with Extended-Release Naltrexone

Author

Latif, Zill-E-Huma

Abstract

Studien undersøker effekt av langtidsvirkende naltrekson på symptomer av angst, depresjon, søvnløshet og kronisk smerter hos opioidavhengige. Langtidsvirkende naltrexon gitt som intramuskulær injeksjon hver 4. uke er et lovende behandlingsalternativ for opioidavhengighet. I en 3-måneders randomisert studie fikk deltakerne behandling med henholdsvis langtidsvirkende naltrekson eller buprenorfine-naloksone. Behandlingene viste like gode resultater med hensyn til reduksjon i symptomer av angst og depresjon, retensjon i behandling og redusert bruk av opiater. Langtidsvirkende naltrekson var mer effektiv mot søvnløshet. Ingen av deltakerne rapporterte økning i smerter. I etterkant av 3-månedene, fikk alle deltakerne tilbud om langtidsvirkende naltrekson i en 9-måneders periode. Alle symptomene ble betydelig bedre i denne perioden. Konklusjonen fra studien er at komorbide symptomer av angst, depresjon og søvnløshet hos opioidavhengige ikke bør hindre bytte fra opioid agonist behandling til opioid antagonist behandling. Deltakerne som ble indusert på langtidsvirkende naltrekson viste ingen økning i smerter.

Published
2019

19. Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone.

Author

Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, and Tanum L

Abstract

Background and Aim: Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term treatment, long-term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long-term XR-NTX treatment and to examine long-term treatment outcomes., Design: In this prospective cohort study, following a parent 1-year study of XR-NTX, participants received treatment with XR-NTX at their own discretion for a maximum of 104 weeks., Setting: Five urban, outpatient addiction clinics in Norway., Participants: Opioid-dependent adults 18-60 years old (n=50) already participating in the parent study., Intervention: XR-NTX administrated as intra-muscular injections (380 mg) every 4 weeks., Measurements: Time in the study, use of opioids and other illicit substances, opioid craving, and treatment satisfaction reported every 4 weeks., Findings: Among 58 participants who completed the 1-year parent study, 50 chose to continue the treatment with XR-NTX. Median prolonged treatment time was 44.0 weeks (95% CI: 25.5-62.5), ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10., Conclusions: Extended-release naltrexone (XR-NTX) was well tolerated in long-term treatment of opioid dependent individuals in Norway already in XR-NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9 to 12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period., (This article is protected by copyright. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results